Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) has been assigned a consensus rating of "Buy" from the seven ratings firms that are presently covering the company, MarketBeat reports. Six analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $18.60.
A number of research firms have recently issued reports on ATYR. HC Wainwright reiterated a "buy" rating and set a $35.00 price objective on shares of Atyr PHARMA in a research note on Friday. Leerink Partners began coverage on shares of Atyr PHARMA in a research note on Tuesday, February 18th. They set an "outperform" rating and a $16.00 price objective on the stock. Cantor Fitzgerald began coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They set an "overweight" rating on the stock. Finally, Leerink Partnrs upgraded shares of Atyr PHARMA to a "strong-buy" rating in a research note on Tuesday, February 18th.
View Our Latest Research Report on Atyr PHARMA
Atyr PHARMA Trading Down 0.5 %
ATYR stock traded down $0.02 during mid-day trading on Friday, reaching $3.97. The company had a trading volume of 2,401,773 shares, compared to its average volume of 1,313,086. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The company has a market capitalization of $333.25 million, a PE ratio of -4.22 and a beta of 0.98. The firm has a 50 day moving average of $3.65 and a 200 day moving average of $3.07. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $4.66.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last issued its earnings results on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. On average, equities analysts predict that Atyr PHARMA will post -0.91 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Atyr PHARMA
A number of hedge funds and other institutional investors have recently bought and sold shares of ATYR. Group One Trading LLC purchased a new stake in Atyr PHARMA during the fourth quarter valued at approximately $26,000. Alterna Wealth Management Inc. purchased a new position in shares of Atyr PHARMA in the fourth quarter worth $36,000. Victory Capital Management Inc. purchased a new position in shares of Atyr PHARMA in the fourth quarter worth $37,000. Raymond James Financial Inc. purchased a new position in shares of Atyr PHARMA in the fourth quarter worth $39,000. Finally, XTX Topco Ltd purchased a new position in shares of Atyr PHARMA in the fourth quarter worth $40,000. Hedge funds and other institutional investors own 61.72% of the company's stock.
About Atyr PHARMA
(
Get Free ReportaTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Featured Articles
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
